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Abstract
Computational drug design tools have become indispensable in the quest for new drugs. 
There is hardly any drug discovery program where computational methods are not 
employed, be it structure‐based or ligand‐based methods. Numerous drug targets have 
been explored for discovery of new drugs using computational methods. In recent times, 
discovery of newer and selective phosphodiesterase as medications for inflammatory 
disorders, CNS disorders, and many other diseases has been the focus of many research 
groups worldwide. Most of these groups have employed computational methods of 
drug design and discovery at different stages of their research. This chapter reviews the 
reported application of computational methods used in the discovery and development 
of phosphodiesterase inhibitors.
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1. Introduction
The early application of computational methods as a means to identify and design phos‐
phodiesterase (PDE) inhibitors goes back to the 1980s where the first reported study tried 
to explain the relation between specific physicochemical properties and potency of known 
inhibitors [1]. The result was the identification of pharmacophore for PDE inhibitors [2]. 
Computational methods of drug design and discovery have impacted the overall process of 
drug discovery in a big way over the last two decades [3, 4]. The cost as well as time of drug 
discovery has been reduced due to the inclusion of computational methods as well as high‐
throughput synthesis and screening. Computational methods have undergone  development 
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at immense pace and newer and more accurate methods have come up. Traditionally, compu‐
tational methods have been classified into structure‐based methods and ligands‐based meth‐
ods [4]. Structure‐based methods like docking‐based virtual screening has been used for new 
lead identification for phosphodiesterase (PDE) inhibitors, while ligand‐based methods such 
as quantitative structure activity relationships (QSAR) have been mostly used for lead opti‐
mization [5–8]. However, ligand‐based methods, such as pharmacophore development, have 
played an important role in many lead discovery programs. Structure‐based methods like 
molecular dynamics (MD) simulations have been used to study the binding of PDE inhibi‐
tors with the enzyme. While the information derived from MD simulations has been used 
to optimize the structure of inhibitors [9–13]. As far as exploring the inhibitor structural fea‐
tures determining selectivity variations, the computational approach could rely on both struc‐
ture‐based and ligand‐based strategies. However, due to high degree of similarity observed 
among all the PDE catalytic sites, the ligand‐based approach could represent a much more 
promising tool to deeply investigate the selectivity issues around PDE inhibitors as compared 
to structure‐based approach.
This chapter aims to provide an update of the recent advances in the field of rational design 
of PDE inhibitors. Attempt has been made to explore both scientific journals as well as patent 
literature.
2. Ligand‐based methods: general aspects and perspective
The most prominently used ligand‐based drug design methods include QSAR and pharmaco‐
phore mapping. There are several reports where QSAR has been used for optimizing the PDE 
inhibition activity of ligands having specific structural scaffolds. Some studies have reported 
unique applications of ligand‐based methods, i.e., ligand‐based homology modeling and 
exploration of selectivity toward specific receptor subtypes.
2.1. PDE10A inhibitors
Among the several PDE subtypes inhibitors, PDE10A inhibitors have attracted enormous 
interest recently for their potential in the treatment of schizophrenia and Huntington’s dis‐
ease, whereby they can fill up the voids present in the current therapeutic approach. In one 
of the recent studies on PDE10A inhibitors, Mondal et al. reported the application of ligands‐
based methods toward optimization of cinnolines as PDE10A inhibitors [14]. 2D‐QSAR, 
HQSAR (hologram quantitative structure activity relationship), pharmacophore mapping, 
and three‐dimensional (3D)–QSAR analyses in combination with structure‐based methods 
like molecular docking and MD simulations were used for the purpose.
Eighty‐one cinnoline derivatives having PDE10A inhibitory activity were used as the data set. 
2D‐QSAR models were developed by multiple linear regression and partial least square (PLS) 
analyses using both atom‐based and whole molecular descriptors. The best model, having 
considerable internal (q2 = 0.812) and external (R2 pred = 0.691) predictabilities, demonstrated 
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importance of atom‐based topological and whole molecular E‐state as well as 3D topological 
indices.
Hologram QSAR, a relatively newly developed QSAR technique, relates biological activity to 
structural fragments [15]. HQSAR eliminates the need for generation of 3D structures, puta‐
tive binding conformations, and molecular alignments. The process of generating HQSAR 
models involve the fragmentation of the data set structures and then hashing into array bins. 
Molecular hologram fingerprints are then generated. Holograms are constructed by cutting 
the fingerprint into strings at various hologram length parameters. After the generation of 
descriptors, partial least square (PLS) methodology is used to find the possible correlation 
between dependent variable (activity) and independent variable (descriptors generated by 
HQSAR structural features) [15]. The best HQSAR model for cinnolines as PDE10A inhibitors 
was found to be statistically significant (q2 = 0.664, R2 pred = 0.513), and it highlighted some 
important structural features.
Pharmacophore mapping was also employed in this case. The pharmacophore hypothesis 
showed the importance of hydrogen bond acceptors and ring aromatic and hydrophobic fea‐
tures for higher activity. The compounds were mapped to the pharmacophore as per their 
activity, and the pharmacophore provided an efficient means of aligning the compounds for 
comparative molecular field analysis (CoMFA) and comparative molecular similarity indices 
analysis (CoMSIA) studies.
Finally, three‐dimensional QSAR methods implemented as CoMFA and CoMSIA were 
applied on the data set. 3D‐QSAR models were generated using two different types of align‐
ment procedures—(1) pharmacophore based and (2) docking based. Docking‐based alignment 
produced better results for both CoMFA (q2 = 0.578; R2 pred = 0.841) and CoMSIA (q2 = 0.610; 
R2 pred = 0.824) methods.
Molecular dynamics (MDs) simulations were also performed for two ligand–receptor com‐
plexes, and the findings of MD simulations were consistent with the interpretations obtained 
from ligand‐based analyses methods described above. The role of hydrogen bond acceptors 
and aromatic and hydrophobic features in determining PDE10A inhibition potential was 
unraveled. The study clearly puts forth guideline for the design and development of cin‐
nolines as potent and selective PDE10A inhibitors and demonstrates the role of ligand‐based 
drug design methods combined with structure‐based drug design (SBDD) methods.
2.2. PDE4 inhibitors
PDE4 has long been considered as target for design of antiinflammatory molecules, and 
numerous PDE4 inhibitors have been developed [16–21]. Quinolines as a third‐generation 
of PDE4 inhibitors show an increased antiinflammatory effect without being dose limited by 
side effects compared to the first‐ and second‐generation of PDE4 inhibitors such as rolipram 
and roflumilast. Recently, newer quinoline derivatives were developed as selective PDE4B 
inhibitors using ligand‐based pharmacophore and atom‐based 3D‐QSAR modeling along 
with structure‐based docking and ADME methods [21].
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These studies, in combination, led to new understanding about the selection of target mol‐
ecules from many candidates. In this case, computational methods were not the primary tools 
used for designing the ligands rather they were used for identifying and confirming the bind‐
ing site of the ligands on PDE4B. The 3D‐QSAR model of PDE4B inhibitors developed for this 
study proved to be reliable with r2 value of 0.96 and q2 value of 0.91. The specific pharmaco‐
phore for PDE4B was then mapped and selected for virtual screening, and the potent PDE4B 
inhibitors were finally confirmed their selectivity ability for PDE4B by docking, ADME analy‐
sis, and MD, and then, molecules were developed as selective PDE4B inhibitors (Figure 1) [21].
2.3. PDE7 inhibitors
Like PDE4, PDE7, a cAMP‐specific phosphodiesterase, is also highly expressed in human 
immune system such as thymus, lymph nodes, spleen, and blood leukocytes, suggesting 
PDE7 as a possible target for treating CNS and airway diseases [22–25]. A recent study by 
Cichero et al. whereby they applied 3D‐QSAR methods for the development of selective PDE 
7 inhibitors is worth noting. Herein, 72 derivatives of thieno[3,2‐d]pyrimidin‐4(3H)‐one were 
selected from literature and were used to develop new selective PDE7 inhibitors [26]. The 
uniqueness of the study was the application of 3D‐QSAR to identify the structural features 
required for the selectivity for a particular target.
Docking‐based 3D‐QSAR followed by redocking was performed to identify the most suitable 
bioactive conformations of derivatives and most comparable binding mode with that of X‐ray 
structure. The conformations of the compounds showed good agreement with the conformations 
in the known PDE7A‐ligand complex. The compounds were further submitted to a CoMFA and 
CoMSIA analysis. Since inhibitors which showed high selectivity for PDE7, rather than PDE4, 
are candidates for antiinflammatory molecules, two models (PDE7 selectivity (model A) and 
Figure 1. In silico strategy to discover PDE4B specific inhibitors.
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PDE4B selectivity (model B)) were established. Predictive models for both the activities were 
obtained, i.e., CoMFA
(model A)
 (optimum number of components (ONC = 6, r2 = 0.946, and standard 
error of estimate, SEE, = 0.292), CoMSIA
(model A)
 (r2 = 0.961, SEE = 0.249), CoMFA
(model B)
 (ONC = 6, 
r
2 = 0.968, and SEE = 0.353), and CoMSIA
(model B)
 (r2 = 0.968 and SEE = 0.356; Figure 2). The role of 
steric, electrostatic, and hydrophobic features in the binding mechanism of ligands to both PDE7 
and PDE4 was identified. The study unraveled structural information for the development of 
new PDE7 inhibitors with high selectivity.
2.4. PDE11 inhibitors
Another unique application of ligand‐based methods was reported by Cichero et al. earlier in 
2013. Since the X‐ray structure of PDE11 was not available, ligand‐based homology  modeling 
Figure 2. CoMFA and CoMSIA models for (a) PDE7 selectivity and (b) PDE4B selectivity (CoMFA: green, favored for 
bulky groups; yellow, disfavored for bulky groups) (CoMSIA: blue, favorable for more positively charged groups; red, 
favorable for less positively charged groups). (Cichero et al. [26] – Published by The Royal Society of Chemistry).
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technique was applied to explore the 3D structure of PDE11 [27]. Consistent with the sequence 
similarity of PDE11 and PDE5, several tadalafil analogs (PDE5 ligands) showed binding 
affinity to PDE11 too [28–30]. Thus, the 3D structure of PDE11 was built on the basis of 
PDE5‐tadalafil complex using homology modeling technique [31]. Besides the conventional 
homology modeling steps such as insertion and deletion of extra atoms during the energy 
minimization stages, evolution, including model building and refinement were performed 
in this specific case. Specifically, residues located in H‐loop and M‐loop were involved in 
obtaining PDE11 structure as they are important for substrate recognition [32]. The coordi‐
nates of PDE11 were derived from PDE5‐tadalafil complex, and the amino acid sequences 
were obtained from the SWISSPROT database. This was followed by the development of 
models using MOE software without significant main chain deviations. AMBER94 force 
field was applied to minimize the structure energy, and Ramachandran plots were applied 
to assess the final obtained model. Successively, reliability of the derived PDE11 model was 
further confirmed by molecular docking and MD simulations with selective PDE11 inhibitors 
and dual PDE5‐PDE11 inhibitors. This study provided new information of target structure 
of PDE11 to design selective PDE11 inhibitors for the treatment of cardiac pathologies [33]. 
The success of this approach is supposedly due to the synergic interaction between theory 
and experiment.
3. Structure‐based methods: general aspects and perspective
Structure‐based drug design (SBDD), as one of the in silico methods, is almost an integral part 
of any drug discovery and development project. These methods, in addition to the binding 
affinity between a specific protein target and a ligand, also provide insight into the interaction 
between the two. This helps in devising substituent modifications around the ligand scaffold 
leading to improved binding [34]. Based on the existing knowledge of 3D structures of PDEs, 
the great potential and success of structure‐based computational methods have been visible 
in the development of newer PDE inhibitors. In addition to the routine screening and interac‐
tion studies, many unique applications of structure‐based methods have been reported for the 
development of PDE inhibitors.
3.1. Selective PDE4B inhibitors
In one of the recent reports by Jing Li and team, virtual screening of natural product data‐
base was carried out to discover novel selective PDE4B inhibitors from natural products data‐
base [35]. Structure‐based approaches like docking and molecular dynamics simulation were 
used for the purpose, although pharmacophore‐based screening was also employed as ini‐
tial filter. The screening led to the identification of four potential PDE4B‐selective inhibitors 
(ZINC67912770, ZINC67912780, ZINC72320169, and ZINC28882432; Figure 3). Compared 
to the reference drug (roflumilast), they scored better during the virtual screening process. 
DOCK and Vina were used for docking, and results were agreeable. Binding free energy was 
−317.51, −239.44, −215.52, and −165.77 kJ/mol, which is better than −129.05 kJ/mol of roflumi‐
last. The MD studies also showed that ZINC28882432‐PDE4B complex reached stable RMSD 
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faster than roflumilast‐PDE4B complex. This study demonstrates the successful application of 
MD in a virtual screening workflow.
3.2. Selective PDE5 inhibitors
The cross‐reactivity of PDE 5 inhibitors like sildenafil, vardenafil, and tadalafil with hERG1 is 
well documented. However, hERG1 is proven to be involved in the regulation of human ven‐
tricular myocyte action potential, thus blocking this hERG channel results in the function loss of 
the PDE5 inhibitors and further leads to serious life‐threatening disorders and cardiovascular 
problems [36, 37]. One of the recent studies explored this cross‐reactivity using docking. Open 
and open‐inactivated states of hERG1 potassium channel were used as protein structures and 
binding interaction patterns and affinity between the proteins and PDE5 inhibitors were studied 
[38]. Three different structure‐based docking tools including GOLD, MOE, and AUTODOCK 
were applied to identify the binding interactions between Sildenafil and hERG1 channel. In 
open‐state conformation of hERG1, both GOLD and MOE showed common interactions and 
further AUTODOCK and GOLD scoring analysis gave a 2.16 kcal/mol lower energy compared 
to open‐inactivated state. In open‐inactivated conformation of hERG1, three docking tools 
showed similar interaction patterns but MOE docking results were more specific in terms of H‐
bonding, distance, and key residues. To further confirm the key residues which are responsible 
for binding affinity to the hERG1 channel, in silico alanine mutagenesis study was performed, 
and new promising molecules were designed based on the interaction patterns and alanine 
mutagenesis studies. MD simulations were finally used to confirm that the complex of the new 
compounds with hERG1 channel is much less stable than that with PDE5. This study showed 
new approach toward the design of PDE5 inhibitors with lower affinity for hERG1 channels.
In another study dealing with cross‐reactivity of PDE5 inhibitors, Kayık and team explored 
cross‐reactivity of PDE5 inhibitors with PDE6 and PDE11 [39]. The major challenge of their 
study was designing novel PDE5 inhibitors with decreased cross‐reactivity with PDE6 and 
PDE11. For this aim, the similarity‐based virtual screening protocol was applied for the “clean 
drug‐like subset of ZINC database that contained more than 20 million small compounds. 
Moreover, molecular dynamics (MD) simulations of selected hits complexed with PDE5 
and off‐targets were performed to get insights for structural and dynamical behaviors of the 
selected molecules as selective PDE5 inhibitors. Since tadalafil blocks hERG1 K channels in 
concentration‐dependent manner, the cardiotoxicity prediction of the hit molecules was also 
tested. The study revealed important structural information for the design of novel, safe, and 
selective PDE5 inhibitors by applying SBDD.
Figure 3. Structure of ZINC28882432 a PDE4B inhibitor from natural sources identified by virtual screening.
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3.3. Dual PDE1 and PDE5 inhibitors
Dual inhibitors of PDE1 and PDE 5 are known to produce vasodilation and have thus been 
explored as therapeutic agents for the treatment of different cardiovascular diseases, i.e., 
hypertension, angina, heart failure, and arteriosclerosis [40, 41]. Yamazaki et al. employed a 
ligand‐based virtual screening for the identification of novel lead candidates with potent dual 
inhibition of PDE1 and 5 [42]. These compounds have application in the treatment of different 
cardiovascular diseases, i.e., hypertension, angina, heart failure, and arteriosclerosis [42, 43].
They applied virtual screening that consists of classification and regression tree (CART) analy‐
sis with the utilization of 168 2‐center pharmacophore descriptors and 12 macroscopic descrip‐
tors which can result in finding of new lead compounds and drug candidates efficiently. The 
method applied started with the learning step of CART analysis where a prediction model is 
configured, and the explanatory variables are selected as per the discrimination index of train‐
ing set. These variables should be independent from each other.
In the following step, they checked the potential energy term and solvation energy, which are the 
main constituents of the binding energy used in molecular modeling and simulation, to select 
the most suitable set of explanatory variables. The potential and solvation energy was obtained 
by summing up electrostatic potential term, van der Waals potential term, solvation free energy 
term, and hydrogen bond energy term. This situation is represented qualitatively by pharma‐
cophore where it provides the binding features with the position of these features. In chemo‐
informatic analysis, the pharmacophore descriptor is either a part or all of pharmacophore. The 
n‐center pharmacophore descriptor is the number of features that participate in binding and the 
distance between them, for example, 2‐center, 3‐center, etc. In this research, they adapted 2 for n 
to reduce the number of explanatory variables. Six binding features were used with eight classes 
of distance between them, this gives 168 two‐center pharmacophore descriptor.
In next stage, the virtual screening has been performed to screen the library of commercially 
available chemical compounds that was supplied by SPECS Inc. for PDE5 inhibitor activity. 
Based on Lipinski’s rule of five, the compounds with undesirable physicochemical and phar‐
macokinetic properties were filtered out, followed by selection of compounds with desirable 
inhibition activities for PDE5 by CART model. The next step involved the selection of struc‐
turally diverse 100 compounds. Finally, 19 drug‐like compounds out of 100 were selected and 
obtained from SPECS Inc. and assayed in vitro to test their inhibitory activity against PDE1 
and PDE5 [42]. The results showed that the virtual screening along with the CART analysis 
have a high prediction capability for biological activity of new chemical compounds.
3.4. Selective PDE1 inhibitors
One of the least explored PDEs as a drug target singly has been PDE1, although it has been 
a combined target with PDE5 for vasodilator drugs [11, 44]. However, some of the studies 
have shown that it is a promising target for the treatment of cognitive impairments [45]. One 
such report by Li et al. recently presented novel PDE1 inhibitors for the treatment of cognitive 
impairments. They applied both ligand‐ and structure‐based drug design methods to discover 
these novel PDE1 inhibitors. Achieving high selectivity among PDE enzymes is challenging, 
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since all PDE enzymes share a high degree of sequence homology in the catalytic domains [46–
50]. They started by analyzing the published PDE inhibitors with various scaffolds and found 
out that pyrazolo[3,4‐d]pyrimidinones, which was reported by Xia and coworkers, could be 
the first step for designing a new, potent, and selective PDE1 inhibitors [51]. At the beginning, 
these compounds were developed as dual inhibitors for both PDE1 and PDE5 [46–49].
According to the available X‐ray crystal structures of human PDE enzymes, a hydrogen bond 
is formed between the N‐7 nitrogen of purine ring in guanine and adjacent amino acid residue 
in catalytic site. In pyrazolo[3,4‐d]pyrimidinone compounds, the hydrogen bond network is 
disrupted due to the shift of nitrogen in pyrozole ring from position 3 to position 2. Li et al. 
designed polycyclic 3‐aminopyrazolo[3,4‐d]pyrimidinone scaffold 2 to reestablish the hydro‐
gen bond through the substitution of amino group at carbon 3 of pyrazole ring [50]. By apply‐
ing a combination of ligand‐based and structure‐based drug design methods, they designed 
numerous novel scaffolds as PDE1 inhibitors. Their work resulted in the discovery of a clini‐
cal candidate (ITI‐214) which has excellent selectivity toward PDE1 (Figure 4). ITI‐214 is now 
in clinical trial phase I and is being tested for its ability in the treatment of cognitive deficits 
associated with neurodegenerative and neuropsychiatric disorders and other CNS and non‐
CNS diseases [45, 50].
3.5. PDE9A inhibitors
Another PDE which has emerged as a promising drug target recently is PDE9A [52]. PDE9A is 
now considered as an important therapeutic target for the treatment of diabetes and Alzheimer’s 
disease (AD) [53]. Most of the inhibitors of PDE9A until recently were based on the pyrazolopy‐
rimidinone scaffold, thus there was need to identify novel scaffolds possessing this activity [54]. 
Zhe Li and team used a combinatorial method including pharmacophores, molecular docking, 
molecular dynamics simulations, binding free energy calculations, and bioassay to discover 
novel PDE9A inhibitors with new scaffolds (Figure 3) [55]. SPECS database containing about 
Figure 4. Structure of ITI‐214, a PDE1 inhibitor in clinical trials.
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200,000 compounds was screened using their combinatorial approach. The combination of 
ligand‐ and structure‐based methods in combinatorial fashion was done with the aim to reduce 
computational cost as structure‐based methods alone are computationally too expensive for 
virtual screening. The results were encouraging as has been the case whenever such combinato‐
rial approach has been employed. Fifteen hits out of 29 molecules (a hit rate of 52%) with five 
novel scaffolds were identified to be PDE9A inhibitors with inhibitory affinities no more than 
50 mM to enrich the structural diversity, different from the pyrazolopyrimidinone‐derived fam‐
ily. The high hit ratio of 52% for this virtual screening method indicated that the combinatorial 
method is a good compromise between computational cost and accuracy. Binding pattern anal‐
yses indicate that those hits with nonpyrazolopyrimidinone scaffolds can bind the same active 
site pocket of PDE9A as classical PDE9A inhibitors. The five novel scaffolds discovered in this 
study can be used for the rational design of PDE9A inhibitors with higher affinities (Figure 5).
3.6. PDE2 inhibitors
PDE2 is a key enzyme that hydrolyzes both cAMP and cGMP. It has been suggested that 
selective PDE2 inhibitors could be a promising therapy for some of the CNS disorders, such as 
Alzheimer’s disease, memory deficit, and depression since PDE2 modulates neuronal signaling 
Figure 5. Virtual screening strategy to discover novel PDE9 inhibitor scaffolds.
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involved in concentration, learning and memory, and emotion [56]. Bo Yang and coworkers 
examined the binding structures and free energies for PDE2 and benzo[1,4]diazepin‐2‐one 
derivatives (PDE2 inhibitors) by combining the molecular docking, molecular dynamics (MD), 
calculations of binding free energy, and binding energy decompositions [57, 58]. Molecular 
docking was performed followed by energy minimization. The docked structures were ana‐
lyzed followed by the selection of the best pose for each ligand. The next step was MD stimu‐
lation. The binding free energy (ΔG
bind
) of PDE2A‐ligand complex was determined based on 
the MD trajectory for each complex [59]. The binding energy decomposition was estimated by 
using molecular mechanism/generalized Born surface area (MM/GBSA) method.
The results put forth important information regarding the PDE2A‐ligand binding patterns 
including the intermolecular interactions, hydrophobic interactions, and hydrogen bonding. 
The estimated PDE2A‐inhibitor binding patterns and the agreement between theoretical and 
experimental outcomes provided a firm base for further design of new, selective, and more 
potent PDE2A inhibitors [57].
In recent years, several potent inhibitors for PDE2 were developed but none reached the 
market due to either lack of selectivity or poor pharmacokinetic properties. This led work 
to focus on the optimization of pharmacokinetic properties of PDE2 inhibitors. Zhang et al. 
tried to discover selective potent PDE2A inhibitors with improved pharmacokinetic proper‐
ties [60–67]. In their study, they described the identification of novel PDE2A inhibitors by 
structure‐based virtual screening. They combined pharmacophore model‐based screening 
and molecular docking along with MD simulations and bioassay to find new selective com‐
pounds with significant improvement in inhibition activity (Figure 6).
Beginning with the selection of small‐molecule database SPECS (comprising almost 200,000 
small molecules) for virtual screening, this database was filtered by Lipinski’s rule of five to 
constitute databaset0 which is the initial data set. The crystal structures of PDE2A in a bound 
Figure 6. Discovery of LHB‐8, a potent PDE2 inhibitor. (Reprinted with permission from Zhang et al. [67] Copyright © 
2017 American Chemical Society).
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state were used to generate the 3D pharmacophore model. This model was applied for mini‐
mizing the size of database through efficient screening of dataset0 to obtain dataset1. Pan‐
assay interfering compound substructures (PAINS) screening was used to obtain dataset2 by 
eliminating the false positive compounds that might interfere with other detecting methods 
and result in false positives.
In the next step, the dataset2 compounds were submitted for molecular docking to predict 
the preliminary optimal binding modes and binding energies between PDE2A and ligand. 
Those compounds with better scores than the reference and proper binding modes consti‐
tuted dataset3. In the last step, MD stimulations and molecular mechanism/Poison‐Boltzman 
surface area (MM‐PBSA) method were applied for more accurate prediction of the binding 
modes and binding energies. AMBER 10.0 was utilized to stimulate the binding of PDE2A 
with the compounds in dataset3, whereas MM‐PBSA was used for the calculation of binding 
free energy. At the end, 30 molecules with optimal binding patterns and top binding energies 
were selected to make up the final dataset. Nine hits out of 30 molecules (a hit rate of 30%) 
were identified with less than 50 μM affinity for PDE2A.
The result of this study was the discovery of new compound LHB‐8 with IC
50
 = 570 nM 
(Figure 4). This compound poses novel scaffold benzo[cd]indol‐2(1H)‐one among PDE2A 
inhibitors, which can be used as the novel scaffold for designing of potent inhibitors of 
PDE2A [67].
3.7. PDE3 inhibitors
One of the early studies reporting the application of structure‐based drug design on PDE3 
inhibitors was done by Fossa et al. [2]. They combined homology modeling techniques with 
docking to gain knowledge about the molecular requirements of selective inhibition of PDE3 
and identified the important amino acids residues for substrate and inhibitor binding. They 
built a homology model of PDE3A catalytic site based on coupling of PDE4B2B crystal struc‐
ture and PDE3A mutagenesis data. The amino acids sequences of PDEs were obtained and 
multiple sequence alignments of PDE isozymes were performed [68–70]. Then, phylogenetic 
relationship was used to calculate the amino acid conservation based on the obtained align‐
ments followed by prediction of secondary structure [71, 72]. Fold recognition and sequence 
to structure alignment was also done during the course [2, 73]. 3D models were generated by 
the application of restraint‐based homology modeling methods [74]. At the end, the Amber 
force field was applied for energy minimization, and the generalized Born solvation model as 
implemented in AMBER was used for the calculation of molecular mechanic. The structural 
evaluation of the model proved that it is suitable for docking studies [75].
Another study was proposed by Kim et al. where they used a virtual screening approach to 
discover novel PDE3 inhibitors for obesity treatment. They started with the analysis of the 
structural features of the known PDE3 inhibitors and screening of virtual library with 30,000 
diverse compounds, followed by docking study based on the 3D structure of PDE3B. In this 
work, Kim et al. built 3D structures of PDE3B‐ligand complex by utilizing a cocrystal structure. 
Docking was carried out, and 80 compounds with low energy conformation were identified 
by docking. These compounds were examined for their adipocyte lipolysis activity and finally 
Quantitative Structure-activity Relationship18
four structurally unrelated compounds were identified. Among these leads, the most potent 
compound has IC
50
 = 14.8 nM for PDE3A activity and 88.4 nM for PDE3B activity [76].
4. Future perspective
Apart from those discussed in the previous section, there are many more examples of success‐
ful application of in silico methods in the discovery and design of PDE inhibitors. The appli‐
cations are very diverse ranging from lead discovery to optimization. However, the major 
problem with various PDE subtype inhibitors, designed or discovered, is the lack of selectiv‐
ity. Although with the application of computational methods inhibitors with significant selec‐
tivity for PDE subtypes have been designed lately, still none of them have been able to make 
it to the market. The advancement in computational hardware and MD simulation methods 
will be the major boost for solving the selectivity problem in future. These advancements 
will allow more deeper studies on a tinier time scale allowing the computational chemist 
to capture interactions and structural features required for high degree of selectivity. These 
developments bring hope that the unfulfilled potential of various PDE inhibitors will be real‐
ized in near future.
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